Cancer Research Meeting Calendar EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakau, M.
Right arrow Articles by Taketo, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakau, M.
Right arrow Articles by Taketo, M. M.
[Cancer Research 62, 4549-4553, August 15, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Hepatocellular Carcinoma Caused by Loss of Heterozygosity in Lkb1 Gene Knockout Mice1

Masayuki Nakau, Hiroyuki Miyoshi, Michael F. Seldin, Masayuki Imamura, Masanobu Oshima and Makoto M. Taketo2

Departments of Pharmacology [M N., H. M., M. O., M. M. T.] and Surgery [M. N., M. I.], Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan; The Institute of Experimental Animal Sciences, Osaka University Medical School, Osaka 565-0871, Japan [H. M.]; and Rowe Program in Genetics, Department of Biological Chemistry, University of California, Davis, California 95616 [M.F.S.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Germline mutations of the LKB1 gene are associated with Peutz-Jeghers syndrome, which is characterized by mucocutaneous pigmentation and gastrointestinal hamartoma with an increased risk of cancer development. To investigate the role of LKB1 in vivo, we have recently constructed Lkb1 gene knockout mice. Because of Lkb1 gene haploinsufficiency, the heterozygous Lkb1 mice develop gastrointestinal polyps of which the histological characteristics resemble those of the Peutz-Jeghers syndrome hamartomas. Here we demonstrate that the Lkb1 (+/-) mice develop hepatocellular carcinomas (HCCs). In Lkb1 (+/-) mice >50 weeks of age, >70% of the male mice developed HCCs, whereas only 20% of the females had HCCs, showing a sex difference in the susceptibility. Histological examinations revealed various types of HCCs, such as "trabecular," "clear cell," "pseudoglandular," and "sarcomatous" types, which were strikingly similar to those found in human HCCs. Western blotting and PCR analyses showed loss of Lkb1 heterozygosity in all of the HCC tissues examined, indicating a tumor suppressor role of LKB1 in the mouse liver. These results suggest that lack of LKB1 is a novel mechanism for HCC development. Thus, the Lkb1 (+/-) knockout mutant should be an important and useful model for human HCC.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
PJS3 is an autosomal disorder characterized by mucocutaneous pigmentation and gastrointestinal hamartoma, as well as an increased risk of cancer development (1 , 2) . LKB1 (also termed as STK11) on chromosome 19p13.3, encoding a serine/threonine kinase, is a gene of which the germ-line mutations are found in PJS (3 , 4) . Although LKB1 functions have not been thoroughly studied, several pieces of evidence suggest its roles in the cell cycle and apoptosis. Forced expression of LKB1 in tumor cell lines results in cell cycle arrests (5) , and phosphorylation of LKB1 is essential for the cell growth suppression (6 , 7) . LKB1 is also required for the brahma-related gene 1-induced growth arrest (8) . In addition, LKB1 plays a key role in the p53-dependent apoptosis (9) . On the other hand, a knockout mouse study revealed that LKB1 regulates expression of the vascular endothelial growth factor (10) . These data, taken together, suggest that LKB1 mutations may contribute to tumorigenesis through induction of angiogenesis as well as suppression of growth arrest and apoptosis. As we have reported recently, Lkb1 (+/-) mice develop gastrointestinal polyps because of haploinsufficiency of Lkb1, with histological characteristics resembling those of human PJS hamartomas (11) . We have also found that Lkb1 (+/-) mice develop neoplastic lesions in the liver. To date, several transgenic mouse lines have been established as HCC models. As summarized in Table 1Citation , overexpression of various genes or disruption of the fatty acyl-CoA oxidase gene causes HCC development (12, 13, 14, 15, 16) . The long latency >1 year of the tumorigenic process in most transgenic lines suggests that additional genetic alterations are required for HCC development in these mice. Consistent with this hypothesis, hepatic dysplasia is found in earlier stages, associated with atypical mitotic figures, increased aneuploidy, chromosomal breakage, and translocations (17 , 18) . However, precise molecular mechanisms for HCC development have not yet been defined precisely, although these transgenes should act as triggers of a long sequence of events in hepatocarcinogenesis. Here, we characterize HCC developed in Lkb1 (+/-) mice and demonstrate Lkb1 LOH in all of the HCC tissues examined, suggesting a novel molecular mechanism for HCC development.


View this table:
[in this window]
[in a new window]

  		Table 1 Representative transgenic models with spontaneous HCC

 

   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Lkb1 Knockout Mice.
Construction of Lkb1 knockout mice was described previously (11) . At 3 weeks of age, mice were weaned, numbered, and tails were clipped for genomic DNA preparation. Genotypes of the mice were determined by PCR using primers PGKR (5'-CTA AAG CGC ATG CTC CAG ACT-3') and LKB1EX (5'-GGC GTC CCT AGA CAC ATT TCC-3').

Histological Analyses and Immunohistochemistry.
Liver tissues were fixed in PBS-buffered 4% paraformaldehyde, dehydrated, and embedded in paraffin wax before sectioning at 4-µm thickness. For histopathological examinations, sections were stained with H&E. For immunohistochemistry, serial sections were deparaffinized, treated with 0.3% H2O2 in methanol to inactivate endogenous peroxidase, and incubated with anti-PCNA monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 200-fold dilution for 60 min. Immunodetection of PCNA was performed using Vector Stain Elite kit (Vector Research, Burlingame, CA).

PCNA Labeling Index.
Cell proliferation rate was determined as a PCNA labeling index by scoring the average PCNA-positive cells in four randomly selected microscopic fields (x200) for each PCNA-immunostained section.

RT-PCR Analysis.
Total RNA was prepared from the liver tissues using ISOGEN solution (Nippon Gene, Toyama, Japan), and cDNA was synthesized with SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). A pair of primers (E1F; 5'-CTC GTA CGG CAA GGT GAA GGA G-3' and E6R; 5'-TAC AGG CCC GTG GTG ATG TTG T-3') was used to amplify a 585-bp fragment from exon 1 to 6.

LOH Analysis.
Genomic DNA was extracted using ISOGEN solution (Nippon Gene). Two primer sets were used to detect the targeted Lkb1 allele (PGKR and E6R) and the wild-type Lkb1 allele (PJW; 5'-CAA GGA CAT CAA GCC GGG CAA C-3' and E6R), respectively. For microsatellite analysis, D10Mit42 was chosen, the length of which was 191 bp in the 129/Sv and 185 bp in the C57BL/6 background. The primer sequences were obtained from the Jackson Laboratory web site.4

Western Immunoblot Analysis.
Tissue samples were homogenized and sonicated in lysis buffer [10 mM HEPES (pH 7.4), 50 mM NaCl, 50 mM sodium PPi, 50 mM NaF, 5 mM EDTA, 5 mM EGTA, 100 µM Na3VO4, 0.1% Triton X-100, and 500 µM phenylmethylsulfonyl fluoride]. After centrifugation at 2000 x g at 4°C for 10 min, 20 µg of the supernatant protein was separated in a 10% SDS-PAGE. Sheep polyclonal anti-LKB1 antibody (Upstate Biotechnology, Lake Placid, NY) and enhanced chemiluminescence detection system (Amersham Pharmacia, Uppsala, Sweden) were used to detect the specific signals.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Hepatic Lesions in Lkb1 (+/-) Mice.
We have demonstrated recently that Lkb1 (+/-) mice develop gastrointestinal polyps in which submucosal muscle layers form an arborized network, resembling that in the PJS hamartomas (11) . Because PJS patients show an increased risk of developing both benign and malignant tumors in extraintestinal organs, we carefully examined various tissues for any neoplastic lesions. Although the Lkb1 (+/-) mice had no tumors during the first 30 weeks, they developed small nodular foci in the liver afterward (Fig. 1A)Citation . These nodules of usually 1–2 mm in diameter, were found in 1 of 7 male mice (14%) between 31 and 40 weeks of age (Table 2)Citation . After 41 weeks, all 26 of the male mice necropsied (100%) had nodular foci in the liver (Table 2)Citation . Such hepatic lesions were more abundant and severe in the male mice than in the females, indicating a sex difference in the susceptibility. In addition to these small nodules, the Lkb1 (+/-) mice developed large HCC tumors with marked vascularization (Fig. 1B)Citation . The youngest male mouse that had HCC was 48-week-old, >10 weeks older than that with the nodular foci (Table 2)Citation . Thereafter, the incidence of HCC increased gradually with age, and 9 of 12 males (75%) >61 weeks of age developed HCCs. These results suggest that some of the nodular foci progressed into HCCs (see below).



View larger version (105K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Morphological features of the Lkb1 (+/-) mouse hepatic lesions. A and B, gross appearance of multiple small nodules near surface (A; arrowheads) and HCCs (B; arrowheads). C–H, representative histological sections (H & E). Nodular foci (NdFc) consisting of dysplastic hepatocytes (C; arrows), HCCs with trabecular type (D), clear cell type (E), pseudoglandular type with cystic lumens (F; *), sarcomatous types with intraliver invasion (G; arrowheads), and metastatic foci (Mx) in the lung (Lg; H). T and N in D show the tumor (i.e., HCCs) and normal tissues with their border indicated by arrowheads. Bars, A and B, 10 mm; C, 100 µm; and D–H, 200 µm.

 

View this table:
[in this window]
[in a new window]

  		Table 2 Number of Lkb1 heterozygotes with hepatic lesions

 
Histological Characteristics of HCC in Lkb1 (+/-) Mice.
Histological sections of the Lkb1 (+/-) liver stained with H&E revealed that the nodular foci consisted predominantly of large dysplastic hepatocytes with normal nuclear:cytoplasm ratio (Fig. 1C)Citation . The "clear-cell" type hepatocytes were also observed in ~20% of the nodules (data not shown). On the other hand, HCCs developed in the Lkb1 (+/-) mice showed a variety of histological types as shown in Fig. 1, D–GCitation . The most abundant histopathology was the trabecular type, consisting of well-differentiated carcinoma cells (Fig. 1D)Citation . This type is observed in most human HCCs, from which other HCC types are derived (19) . Several other types of HCCs were also observed. As shown in Fig. 1ECitation , the clear cell type HCC was found in some Lkb1 (+/-) livers, suggesting cytoplasmic glycogen accumulations as often seen in the human HCCs (19) . In addition, gland-like structures with large cystic lumen were also observed (Fig. 1FCitation , asterisks), resembling the human pseudoglandular type HCCs (19) . Furthermore, the sarcomatous type HCC was also found in a case, with spindle-shape tumor cells invading into the adjacent normal tissue (Fig. 1GCitation , arrowheads). Thus, the histological characteristics of the Lkb1 (+/-) HCCs are strikingly similar to the representative histopathology in human HCCs (19) , suggesting that similar genetic or epigenetic changes take place in human and Lkb1 (+/-) mouse HCCs. Importantly, lung metastasis was found in 2 of 19 Lkb1 (+/-) males >50 weeks of age (Fig. 1H)Citation .

Cell Replication and Apoptosis in the Hepatic Lesions.
To additionally investigate these hepatic lesions, we determined cell proliferation rate by PCNA staining. In the littermate wild-type mouse liver, few PCNA-stained hepatocytes were detected (0.05%), reflecting the quiescent state of most hepatocytes (Fig. 2, A and E)Citation . In the nodular foci, on the other hand, many PCNA-positive cells were found (9.3%), indicating continuous proliferation of the dysplastic cells (Fig. 2, C and E)Citation . These data, together with the histological findings, suggest that the nodular foci are hepatocellular adenomas. Increased PCNA indices were also found in the HCC sections (5.4%), although not so high as in the nodular foci (Fig. 2, D and E)Citation , possibly because of insufficient oxygen or nutrient supply in the large tumors. Importantly, the normal hepatocytes of the Lkb1 (+/-) mice showed a slightly but significantly higher level of PCNA index (0.75%) than those in the wild-type liver, suggesting hepatic hyperplasia caused by the decreased LKB1 level (Fig. 2, B and E)Citation .



View larger version (70K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Liver cell proliferation rate determined by PCNA staining. A–D, PCNA immunostaining of the sections of wild-type liver (A), nontumor region of Lkb1 (+/-) liver (B), nodular focus (C), and HCC (D). PCNA-stained nuclei are seen in dark brown. The fatty change observed in the normal part (B, C, or D) is not caused by Lkb1 mutation directly, because it is detected also in the age-matched control mice. E, mean PCNA indices shown as percentages of stained cells with ±SD. WT, wild-type mouse liver; NT, nontumor part of Lkb1 (+/-) liver; NdFc, nodular foci; Bars, 100 µm, and *, P < 0.05.

 
Because LKB1 is required for p53 dependent apoptosis (9) , it is possible that disruption of Lkb1 results in suppression of apoptosis. To investigate this possibility, we scored the number of apoptotic bodies in the sections of nodular foci and HCCs. Although few apoptotic bodies were found in the nodular foci (0.18%), the apoptotic rate was rather increased in HCCs (0.9%) than decreased (data not shown). This apoptotic rate in the HCCs was much higher than that of the HCCs in c-myc/TGF-{alpha} transgenic mice (0.07%; Ref. 20 ), suggesting that apoptosis was not suppressed in the Lkb1 (+/-) mouse HCCs.

LOH of the Lkb1 Gene in HCCs.
To investigate the molecular mechanism(s) of hepatocarcinogenesis in the Lkb1 (+/-) mice, we analyzed LKB1 protein expression by Western blotting. LKB1 was expressed in the wild-type liver tissue, and the level in the nontumor part of the Lkb1 (+/-) liver was approximately half of that in the wild-type littermates, reflecting the gene dosage (Fig. 3, A and B)Citation . However, in the HCC tissue, expression of LKB1 was virtually abolished, indicating biallelic inactivation of Lkb1. This is in sharp contrast to the situation of the gastric hamartoma caused by haploinsufficiency of Lkb1, where the expression of the wild-type LKB1 remains at the heterozygous level (11) . To determine the mechanism of Lkb1 inactivation in HCCs, we performed Lkb1 allele-specific RT-PCR. In the targeted Lkb1 allele, exons 2–4 are replaced with the neomycin resistance gene cassette, causing an alternative splicing of the transcript from exon 1 to 5, which should result in a frame-shift mutation in exon 5 (11) . PCR primers for exons 1 and 6 amplified two mRNA species of different lengths from the wild-type and targeted Lkb1 alleles, respectively (Fig. 3C)Citation . Whereas the level of the shorter transcript from the targeted Lkb1 allele remained unchanged in either the normal liver or HCCs, the wild-type mRNA level was decreased significantly in the HCC tissues, suggesting inactivation of the wild-type Lkb1 allele. A faint band for the wild-type Lkb1 mRNA in the tumor tissue was likely derived from the nontumor cells of the sinusoid or stroma. Finally, we determined LOH of the Lkb1 gene by genomic PCR analysis (Fig. 3D)Citation . The band intensity was reduced significantly for the wild-type Lkb1 allele in all of the HCC samples analyzed, whereas that for the targeted allele remained unaffected, indicating Lkb1 LOH in the HCC tissues. We also verified LOH for a chromosomal region close to Lkb1 by genomic PCR of the D10Mit42 microsatellite marker (data not shown). These data, taken together, strongly suggest that LKB1 plays a role as a tumor suppressor in the liver and that Lkb1 LOH is the cause of the HCCs in our knockout mice.



View larger version (40K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Inactivation of the wild-type Lkb1 allele in HCC. A and B, Western blot analysis of nontumor (N) and tumor (T) liver tissues. Gel photograph (A) and mean band intensities shown in bar graph with ±SD (B). The mouse genotypes are shown on top, and the position of LKB1 band on the right. C, allele-specific RT-PCR analysis of wild-type mouse liver (W), and nontumor (N) and tumor (T) tissues of Lkb1 (+/-) liver. Band positions for wild-type Lkb1 cDNA (WT) and targeted Lkb1 cDNA (KO) are shown on the right. Photographs for the G3PDH band are shown at the bottom as calibration controls. D, genomic PCR analysis of wild-type mouse liver (W), and nontumor (N) and tumor (T) tissues of Lkb1 (+/-) liver. Band positions for wild-type Lkb1 gene (WT) and targeted Lkb1 gene (KO) are shown.

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
We have demonstrated recently that haploinsufficiency of the mouse Lkb1 gene causes gastrointestinal hamartomas (11) . In PJS patients, on the other hand, LOH of the LKB1 gene was reported in their gastrointestinal carcinomas, suggesting a tumor suppressor role for LKB1 (21, 22, 23) . Thus, it is conceivable that loss of the wild-type LKB1 gene is necessary for progression from hamartoma to carcinoma in the PJS gut. In the present study, we have demonstrated biallelic inactivation of the Lkb1 gene in all of the HCC tissues examined, suggesting that lack of LKB1 is also responsible for carcinogenesis in the liver. Although HCC has not been reported in PJS patients, this difference between the human and mouse may be attributable to different susceptibilities to the stimuli that cause LKB1/Lkb1 LOH between the two species. It would also be important to determine whether expression of LKB1 is altered in spontaneous human HCC cases.

Although it has been reported that LKB1 plays a role in the cell cycle arrest and p53-dependent apoptosis (5, 6, 7, 8, 9) , we did not find any significant suppression of apoptosis in the Lkb1 mouse HCCs compared with other transgenic models. However, it is conceivable that Lkb1 LOH suppresses elimination of the hepatocytes with mutations during early stages of hepatocarcinogenesis, allowing transformed cells to colonize. Such a molecular mechanism for HCC development was suggested in other HCC mouse models as well (12) . In TGF-{alpha}/c-myc transgenic mice, hepatocyte dysplasia with atypical mitotic figures is observed before the HCC development (17) . In addition, transplantation of such dysplastic tissues to nude mice gives rise to HCC, suggesting the presence of "initiated" cells in the dysplastic livers (17) . In other transgenic mice overexpressing hepatitis B virus antigens, mutant {alpha}-1-antitrypsin or urokinase-type plasminogen activator, the transgene product is toxic to but not directly tumorigenic in the hepatocytes (12) . During the regeneration from the chronic liver injury caused by the transgene product, transformed hepatocytes appear to be selected and form tumors in these models. Accordingly, it is conceivable that Lkb1 LOH causes similar changes to those in the early transformed hepatocytes in the transgenic models. To characterize such changes, it should be interesting to investigate the gene expression profile in HCCs in the Lkb1 (+/-) mice using gene microarrays.

It has been demonstrated recently that SMAD4, a cytoplasmic messenger of the TGF-ß signal, can bind to LKB1 through LIP1 (for LKB1 interacting protein 1), and that inhibition of LKB1 suppresses TGF-ß signaling (24) . Thus, it is conceivable that TGF-ß signaling is down-regulated in HCCs of the Lkb1 (+/-) mice. Because TGF-ß acts as a potent inhibitor of cell growth, and an apoptosis inducer for epithelial cells and hepatocytes (25 , 26) , a decreased responsiveness to TGF-ß may contribute to HCC development. In the HCCs of TGF-{alpha}/c-myc mice, expression of TGF-ß type II receptor is down-regulated (27) . Furthermore, two mutant mouse lines of the TGF-ß type II receptor gene, heterozygous knockout line and dominant-negative transgenic line, also show an increased susceptibility to chemical liver carcinogenesis (28 , 29) . Therefore, another mechanism for hepatocarcinogenesis in the Lkb1 (+/-) mice may be inhibition of the TGF-ß signal, causing suppression of growth inhibition and apoptosis.

Lkb1 (+/-) mice develop small nodular foci of hepatocellular adenoma with continuous cell proliferation, which may be a precursor of HCC. In the present study, we have determined Lkb1 LOH in HCC but not yet in these adenomatous nodules, because of the limited sample amounts. To precisely understand the molecular mechanisms of hepatocellular adenoma initiation and its progression to HCC, it should be determined whether Lkb1 LOH occurs in these early lesions. Such an analysis is in progress using samples obtained by laser-captured microdissection.

In conclusion, we have demonstrated that biallelic inactivation of the Lkb1 gene is a novel mechanism of HCC formation in the mouse. The Lkb1 heterozygote should be an important and useful model to elucidate the molecular mechanism underlying hepatocarcinogenesis.


   ACKNOWLEDGMENTS
 
We thank Tsutomu Kurosawa for encouragement.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by grants from Takeda Science Foundation, the Ministry of Education, Culture, Sports, Science and Technology, Japan, and from the Organization of Pharmaceutical Safety and Research, Japan Back

2 To whom requests for reprints should be addressed, at Department of Pharmacology, Graduate School of Medicine, Kyoto University, Yoshida-Konoé-cho, Sakyo-ku, Kyoto 606-8501, Japan. E-mail: taketo{at}mfour.med.kyoto-u.ac.jp Back

3 The abbreviations used are: PJS, Peutz-Jeghers syndrome; LOH, loss of heterozygosity; RT-PCR, reverse transcription-PCR; TGF, transforming growth factor; HCC, hepatocellular carcinoma; PCNA, proliferating cell nuclear antigen. Back

4 Internet address: http://www.mgd.informatics.jax.org. Back

Received 4/19/02. Accepted 6/26/02.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Giardiello F. M., Welsh S. B., Hamilton S. R., Offerhaus G. J. A., Gittelsohn A. M., Booker S. V., Krush A. J., Yardley J. H., Luk G. D. Increased risk of cancer in the Peutz-Jeghers syndrome. N. Engl. J. Med., 316: 1511-1514, 1987.[Abstract]
  2. Spigelman A. D., Murday V., Phillips R. K. S. Cancer and the Peutz-Jeghers syndrome. Gut, 30: 1588-1590, 1989.[Abstract/Free Full Text]
  3. Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A., Bignell G., Warren W., Aminoff M., Höglund P., Järvinen H., Kristo P., Pelin K., Ridanpää M., Salovaara R., Toro T., Bodmer W., Olschwang S., Olsen A. S., Stratton M. R., de la Chapelle A., Aaltonen L. A. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature (Lond.), 391: 184-187, 1998.[Medline]
  4. Jenne D. E., Reimann H., Nezu J., Friedel W., Loff S., Jeschke R., Muller O., Back W., Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet., 18: 38-43, 1998.[Medline]
  5. Tiainen M., Ylikorkala A., Mäkelä T. P. Growth suppression by Lkb1 is mediated by a G1 cell cycle arrest. Proc. Natl. Acad. Sci. USA, 96: 9248-9251, 1999.[Abstract/Free Full Text]
  6. Collins S. P., Reoma J. L., Gamm D. M., Uhler M. D. LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochem. J., 345: 673-680, 2000.
  7. Sapkota G. P., Kieloch A., Lizcano J. M., Lain S., Arthur J. S. C., Williams M. R., Morrice N., Deak M., Alessi D. R. Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome. LKB1/STK11, at Ser431 by p90RSK and cAMP-dependent protein kinase, but not its farnesylation at Cys433, is essential for LKB1 to suppress cell growth. J. Biol. Chem., 276: 19469-19482, 2001.[Abstract/Free Full Text]
  8. Marignani P. A., Kanai F., Carpenter C. L. LKB1 associates with Brg1 and is necessary for Brg1-induced growth arrest. J. Biol. Chem., 276: 32415-32418, 2001.[Abstract/Free Full Text]
  9. Karuman P., Gozani O., Odze R. D., Zhou X. C., Zhu H., Shaw R., Brien T. P., Bozzuto C. D., Ooi D., Cantley L. C., Yuan J. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol. Cell, 7: 1307-1319, 2001.[Medline]
  10. Ylikorkala A., Rossi D. J., Korsisaari N., Luukko K., Alitalo K., Henkemeyer M., Mäkelä T. P. Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science (Wash. DC), 293: 1323-1326, 2001.[Abstract/Free Full Text]
  11. Miyoshi H., Nakau M., Ishikawa T., Seldin M. F., Oshima M., Taketo M. M. Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. Cancer Res., 62: 2261-2266, 2002.[Abstract/Free Full Text]
  12. Santoni-Rugiu E., Thorgeirsson S. Transgenic animals as models for hepatocarcinogenesis Strain A. Diehl A. eds. . Liver Growth and Repair, 100-142, Chapman and Hall London 1998.
  13. Dagli M. L. Z., Ward J. M., Merlino G., Enomoto A., Maronpot R. R. Hepatic pathology of genetically engineered mice Ward J. M. Mahler J. F. Maronpot R. R. Sundberg J. P. eds. . Pathology of Genetically Engineered Mice, 317-335, Iowa State University Press Ames, Iowa 2000.
  14. Wang R., Ferrell L. D., Faouzi S., Maher J. J., Bishop J. M. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol., 153: 1023-1033, 2001.[Abstract/Free Full Text]
  15. Conner E. A., Lemmer E. R., Omori M., Wirth P. J., Factor V. M., Thorgeirsson S. S. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene, 19: 5054-5062, 2000.[Medline]
  16. Deane N. G., Parker M. A., Aramandla R., Diehl L., Lee W-J., Washington M. K., Nanney L. B., Shyr Y., Beauchamp R. D. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res., 61: 5389-5395, 2001.[Abstract/Free Full Text]
  17. Santoni-Rugiu E., Nagy P., Jensen M. R., Factor V. M., Thorgeirsson S. S. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-{alpha}. Am. J. Pathol., 149: 407-428, 1996.[Abstract]
  18. Sargent L. M., Sanderson N. D., Thorgeirsson S. S. Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor {alpha} transgenes. Cancer Res., 56: 2137-2142, 1996.[Abstract/Free Full Text]
  19. Ishak K. G., Anthony P. P., Sobin L. H. . Histological Typing of Tumours of the Liver, Ed. 2. WHOX, 11-17, Springer-Verlag Berlin 1994.
  20. Santoni-Rugiu E., Jensen M. R., Thorgeirsson S. S. Disruption of the pRB/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor {alpha}. Cancer Res., 58: 123-134, 1998.[Abstract/Free Full Text]
  21. Resta N., Simone C., Mareni C., Montera M., Gentile M., Susca F., Gristina R., Pozzi S., Bertario L., Bufo P., Carlomagno N., Ingrosso M., Rossini F. P., Tenconi R., Guanti G. STK11 mutations in Peutz-Jeghers syndrome and sporadic colon cancer. Cancer Res., 58: 4799-4801, 1998.[Abstract/Free Full Text]
  22. Gruber S. B., Entius M. M., Petersen G. M., Laken S. J., Longo P. A., Boyer R., Levin A. M., Mujumdar U. J., Trent J. M., Kinzler K. W., Vogelstein B., Hamilton S. R., Polymeropoulos M. H., Offerhaus G. J., Giardiello F. M. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res., 58: 5267-5270, 1998.[Abstract/Free Full Text]
  23. Entius M. M., Keller J. J., Westerman A. M., van Rees B. P., van Velthuysen M-L. F., de Goeij A. F. P. M., Wilson J. H. P., Giardiello F. M., Offerhaus G. J. A. Molecular genetic alterations in hamartomatous polyps and carcinomas of patients with Peutz-Jeghers syndrome. J. Clin. Pathol., 54: 126-131, 2001.[Abstract/Free Full Text]
  24. Smith D. P., Rayter S. I., Niederlander C., Spicer J., Jones C. M., Ashworth A. LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers syndrome kinase LKB1. Hum. Mol. Genet., 10: 2869-2877, 2001.[Abstract/Free Full Text]
  25. Fausto N., Laird A. D., Webber E. M. Role of growth factors and cytokines in hepatic regeneration. FASEB J., 9: 1527-1536, 1995.[Abstract]
  26. Massagué J. TGF-ß signal transduction. Annu. Rev. Biochem., 67: 753-791, 1998.[Medline]
  27. Santoni-Rugiu E., Jensen M. R., Factor V. M., Thorgeirsson S. S. Acceleration of c-myc-induced hepatocarcinogenesis by co-expression of transforming growth factor (TGF)-{alpha} in transgenic mice is associated with TGF-ß1 signaling disruption. Am. J. Pathol., 154: 1693-1700, 1999.[Abstract/Free Full Text]
  28. Im Y-H., Kim H. T., Kim I. Y., Factor V. M., Hahm K-B., Anzano M., Jang J-J., Flanders K., Haines D. C., Thorgeirsson S. S., Sizeland A., Kim S-J. Heterozygous mice for the transforming growth factor-ß type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. Cancer Res., 61: 6665-6668, 2001.[Abstract/Free Full Text]
  29. Kanzler S., Meyer E., Lohse A. W., Schirmacher P., Henninger J., Galle P. R., Blessing M. Hepatocellular expression of a dominant-negative mutant TGF-ß type II receptor accelerated chemically induced hepatocarcinogenesis. Oncogene, 20: 5015-5024, 2001.[Medline]



This article has been cited by other articles:


Home page
 Physiol. Rev.Home page
M. Jansen, J. P. ten Klooster, G. J. Offerhaus, and H. Clevers
LKB1 and AMPK Family Signaling: The Intimate Link Between Cell Polarity and Energy Metabolism
Physiol Rev, July 1, 2009; 89(3): 777 - 798.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Z. Xie, Y. Dong, J. Zhang, R. Scholz, D. Neumann, and M.-H. Zou
Identification of the Serine 307 of LKB1 as a Novel Phosphorylation Site Essential for Its Nucleocytoplasmic Transport and Endothelial Cell Angiogenesis
Mol. Cell. Biol., July 1, 2009; 29(13): 3582 - 3596.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Rodriguez-Nieto and M. Sanchez-Cespedes
BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer
Carcinogenesis, April 1, 2009; 30(4): 547 - 554.
[Abstract] [Full Text] [PDF]

Home page
 Acta Biochim Biophys SinHome page
D. Fan, C. Ma, and H. Zhang
The molecular mechanisms that underlie the tumor suppressor function of LKB1
Acta Biochim Biophys Sin, February 1, 2009; 41(2): 97 - 107.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
A. K. Rustgi
The genetics of hereditary colon cancer
Genes & Dev., October 15, 2007; 21(20): 2525 - 2538.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Kojima, H. Miyoshi, H. C. Clevers, M. Oshima, M. Aoki, and M. M. Taketo
Suppression of Tubulin Polymerization by the LKB1-Microtubule-associated Protein/Microtubule Affinity-regulating Kinase Signaling
J. Biol. Chem., August 10, 2007; 282(32): 23532 - 23540.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P.-Y. Zeng and S. L. Berger
LKB1 Is Recruited to the p21/WAF1 Promoter by p53 to Mediate Transcriptional Activation.
Cancer Res., November 15, 2006; 66(22): 10701 - 10708.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Upadhyay, C. Liu, A. Chatterjee, M. O. Hoque, M. S. Kim, J. Engles, W. Westra, B. Trink, E. Ratovitski, and D. Sidransky
LKB1/STK11 Suppresses Cyclooxygenase-2 Induction and Cellular Invasion through PEA3 in Lung Cancer
Cancer Res., August 15, 2006; 66(16): 7870 - 7879.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Wilson, C. Bonnet, C. Guy, S. Idziaszczyk, J. Colley, V. Humphreys, J. Maynard, J. R. Sampson, and J. P. Cheadle
Tsc1 Haploinsufficiency without Mammalian Target of Rapamycin Activation Is Sufficient for Renal Cyst Formation in Tsc1+/- Mice
Cancer Res., August 15, 2006; 66(16): 7934 - 7938.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
H Mehenni, N Resta, J-G Park, M Miyaki, G Guanti, and M C Costanza
Cancer risks in LKB1 germline mutation carriers
Gut, July 1, 2006; 55(7): 984 - 990.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
A J Bauer and C A Stratakis
The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis
J. Med. Genet., November 1, 2005; 42(11): 801 - 810.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J.-S. Lee, J. W. Grisham, and S. S. Thorgeirsson
Comparative functional genomics for identifying models of human cancer
Carcinogenesis, June 1, 2005; 26(6): 1013 - 1020.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
D. G. Hardie
The AMP-activated protein kinase pathway - new players upstream and downstream
J. Cell Sci., November 1, 2004; 117(23): 5479 - 5487.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. M. Ward and D. E. Devor-Henneman
Mouse Models of Human Familial Cancer Syndromes
Toxicol Pathol, January 1, 2004; 32(1_suppl): 90 - 98.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
A. I. Jimenez, P. Fernandez, O. Dominguez, A. Dopazo, and M. Sanchez-Cespedes
Growth and Molecular Profile of Lung Cancer Cells Expressing Ectopic LKB1: Down-Regulation of the Phosphatidylinositol 3'-Phosphate Kinase/PTEN Pathway
Cancer Res., March 15, 2003; 63(6): 1382 - 1388.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakau, M.
Right arrow Articles by Taketo, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakau, M.
Right arrow Articles by Taketo, M. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online